Malattia di Alzheimer: La diagnosi tra ricerca, prassi clinica ed etica

Translated title of the contribution: Diagnosing Alzheimer's disease: From research to clinical practice and ethics

Daniela Tarquini, Eugenio Pucci, Maddalena Gasparini, Silvia Zullo, Pietro Tiraboschi, Virginio Bonito, Carlo Alberto Defanti

Research output: Contribution to journalArticle

Abstract

In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.

Original languageItalian
Pages (from-to)295-299
Number of pages5
JournalRecenti Progressi in Medicina
Volume105
Issue number7-8
Publication statusPublished - 2014

Fingerprint

Clinical Ethics
Alzheimer Disease
Dementia
Biomarkers
Research
Drug Industry
Amyloid
Positron-Emission Tomography
Cerebrospinal Fluid
Central Nervous System
Pressure
Incidence
Brain
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tarquini, D., Pucci, E., Gasparini, M., Zullo, S., Tiraboschi, P., Bonito, V., & Defanti, C. A. (2014). Malattia di Alzheimer: La diagnosi tra ricerca, prassi clinica ed etica. Recenti Progressi in Medicina, 105(7-8), 295-299.

Malattia di Alzheimer : La diagnosi tra ricerca, prassi clinica ed etica. / Tarquini, Daniela; Pucci, Eugenio; Gasparini, Maddalena; Zullo, Silvia; Tiraboschi, Pietro; Bonito, Virginio; Defanti, Carlo Alberto.

In: Recenti Progressi in Medicina, Vol. 105, No. 7-8, 2014, p. 295-299.

Research output: Contribution to journalArticle

Tarquini, D, Pucci, E, Gasparini, M, Zullo, S, Tiraboschi, P, Bonito, V & Defanti, CA 2014, 'Malattia di Alzheimer: La diagnosi tra ricerca, prassi clinica ed etica', Recenti Progressi in Medicina, vol. 105, no. 7-8, pp. 295-299.
Tarquini D, Pucci E, Gasparini M, Zullo S, Tiraboschi P, Bonito V et al. Malattia di Alzheimer: La diagnosi tra ricerca, prassi clinica ed etica. Recenti Progressi in Medicina. 2014;105(7-8):295-299.
Tarquini, Daniela ; Pucci, Eugenio ; Gasparini, Maddalena ; Zullo, Silvia ; Tiraboschi, Pietro ; Bonito, Virginio ; Defanti, Carlo Alberto. / Malattia di Alzheimer : La diagnosi tra ricerca, prassi clinica ed etica. In: Recenti Progressi in Medicina. 2014 ; Vol. 105, No. 7-8. pp. 295-299.
@article{367baaec0d9049578ba6dbcf237272fe,
title = "Malattia di Alzheimer: La diagnosi tra ricerca, prassi clinica ed etica",
abstract = "In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.",
keywords = "Alzheimer's disease, Biomedical research, Clinical ethics, Diagnosis, Mild cognitive impairment",
author = "Daniela Tarquini and Eugenio Pucci and Maddalena Gasparini and Silvia Zullo and Pietro Tiraboschi and Virginio Bonito and Defanti, {Carlo Alberto}",
year = "2014",
language = "Italian",
volume = "105",
pages = "295--299",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "7-8",

}

TY - JOUR

T1 - Malattia di Alzheimer

T2 - La diagnosi tra ricerca, prassi clinica ed etica

AU - Tarquini, Daniela

AU - Pucci, Eugenio

AU - Gasparini, Maddalena

AU - Zullo, Silvia

AU - Tiraboschi, Pietro

AU - Bonito, Virginio

AU - Defanti, Carlo Alberto

PY - 2014

Y1 - 2014

N2 - In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.

AB - In 2011, the so-called Dubois criteria introduced the use of biomarkers in research (in particular, brain amyloid positron emission tomography imaging and the cerebrospinal fluid levels of tau/fosfo-tau and beta-amyloid 1-42) for the early or preclinical diagnosis of Alzheimer's disease. Even so, we are looking at an increased use of these markers in clinical practice. In the 1960s, Alzheimer's disease was considered a rare form of presenile dementia, but gradually it has been recognized as the prevalent form of old-age dementia. As a consequence, what was once regarded as an inevitable outcome of old age is now recognized as a true disease. Several factors contributed to this paradigm shift, in particular a longer lifespan, new techniques of in vivo study of the central nervous system, and the pressure exerted by the pharmaceutical industry and patient groups. The current lack of disease-modifying therapies and the high incidence of mild cognitive impairment, which is a risk factor for dementia, raise a series of clinical ethical problems ranging from how diagnosis is communicated to how resources are used. This article offers a conceptual scheme through which these issues can be addressed. Copyright - Il Pensiero Scientifico Editore.

KW - Alzheimer's disease

KW - Biomedical research

KW - Clinical ethics

KW - Diagnosis

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84904463241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904463241&partnerID=8YFLogxK

M3 - Articolo

C2 - 25072545

AN - SCOPUS:84904463241

VL - 105

SP - 295

EP - 299

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 7-8

ER -